



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Shimkets, Richard A. EXAMINER: Myers, Carla J.
SERIAL NUMBER: 10/644,349 ART UNIT: 1634
FILING: DATE: August 20, 2003
FOR: METHODS FOR DIAGNOSING AND TREATMENT OF CONDITIONS THAT
ALTER PHOSPHATE TRANSPORTIN MAMMALS

Mail Stop IDS
Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:


1. Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (1 pages) in duplicate;
3. Copies of Cited references B1, C1-C3 and;
4. Return Postcard

No fee is believed to be due at this time. However, the Commissioner is authorized to charge any additional fees that may be due to Deposit Account No.502648, Reference No.Cura 57 PO (15966-557 PO). A duplicate copy of this transmittal letter is enclosed.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at 203/974-6303, New Haven, Connecticut.

Respectfully submitted,

Date: March 29, 2005


George Yankwak Reg. No. 26,824
c/o CuraGen Corporation
555 Long Wharf Drive
New Haven, CT 06511
Tel: (203) 974-6303



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Shimkets, Richard A. EXAMINER: Myers, Carla J.
SERIAL NUMBER: 10/644,349 ART UNIT: 1634
FILING DATE: August 20, 2003
FOR: METHODS FOR DIAGNOSING AND TREATMENT OF CONDITIONS THAT
ALTER PHOSPHATE TRANSPORTIN MAMMALS

Mail Stop IDS
Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application. The order of presentation of the references should not be construed as an indication of the importance of the references. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits in the above-identified case. Accordingly, no fee or certification is required. 37 C.F.R. §1.97.


A copy of each of the references is enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs, the enclosed form PTO-1449 to evidence that the cited information has been fully considered by Patent and Trademark Office during the examination of this application.

By Submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is

considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b); and (3) the information cited in the Statement is, or considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statement by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 502648, Reference No. Cura 57 PO (15966-557 PO).


Respectfully submitted,



Date: March 29, 2005

George Yanwak, Reg. No. 26,824
c/o CuraGen Corporation
555 Long Wharf Drive
New Haven, CT 06511
Tel: (203) 974-6303

Date of Deposit: 03/29/2005



Please type a plus sign (+) in this box



PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/644,349
	Filing Date	08/20/2003
	First Named Inventor	Shimkets, Richard A.
	Group Art Unit	1634
	Examiner Name	Myers, Carla J.
	Attorney Docket Number	Cura 57 PO (15966-557 PO)

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1						

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	B1	WO 00/60085	Millennium Pharmaceuticals, Inc.	10/12/2000	x

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Jeffers, M., R. Shimkets, et al. (2001). "Identification of a novel human fibroblast growth factor and characterization of its role in oncogenesis." Cancer Res 61(7): 3131-8.
	C2	Kirikoshi, H., N. Sagara, et al. (2000). "Molecular cloning and characterization of human FGF-20 on chromosome 8p21.3-p22." Biochem Biophys Res Commun 274(2): 337-43.
	C3	International Search Report for PCT/US04/27017, mailed on March 14, 2005.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.